PMID- 35305871
OWN - NLM
STAT- MEDLINE
DCOM- 20220525
LR  - 20220616
IS  - 1557-3117 (Electronic)
IS  - 1053-2498 (Linking)
VI  - 41
IP  - 6
DP  - 2022 Jun
TI  - Oral anticoagulants (NOAC and VKA) in chronic thromboembolic pulmonary 
      hypertension.
PG  - 716-721
LID - S1053-2498(22)01804-6 [pii]
LID - 10.1016/j.healun.2022.02.002 [doi]
AB  - EXPERT was an international, multicenter, prospective, uncontrolled, 
      non-interventional cohort study in patients with pulmonary hypertension treated 
      with riociguat. Patients were followed for 1-4 years, and the primary outcomes 
      were adverse events (AEs) and serious AEs (SAEs), including embolic/thrombotic 
      and hemorrhagic events. Here we report data on patients with chronic 
      thromboembolic pulmonary hypertension (CTEPH) receiving a vitamin K antagonist 
      (VKA; n = 683) or a non-vitamin K antagonist oral anticoagulant (NOAC; n = 198) 
      at baseline. AEs and SAEs were reported in 438 patients (64.1%) and 257 patients 
      (37.6%), respectively, in the VKA group, and in 135 patients (68.2%) and 74 
      patients (37.4%) in the NOAC group. Exposure-adjusted hemorrhagic event rates 
      were similar in the two groups, while exposure-adjusted embolic and/or thrombotic 
      event rates were higher in the NOAC group, although the numbers of events were 
      small. Further studies are required to determine the long-term effects of 
      anticoagulation strategies in CTEPH.
CI  - Copyright (c) 2022 The Authors. Published by Elsevier Inc. All rights reserved.
FAU - Humbert, Marc
AU  - Humbert M
AD  - Universite Paris-Saclay, Inserm U999, Service de Pneumologie et Soins Intensifs 
      Respiratoires, Hopital Bicetre, Assistance Publique Hopitaux de Paris, Le 
      Kremlin-Bicetre, France. Electronic address: marc.humbert@aphp.fr.
FAU - Simonneau, Gerald
AU  - Simonneau G
AD  - Universite Paris-Saclay, Inserm U999, Service de Pneumologie et Soins Intensifs 
      Respiratoires, Hopital Bicetre, Assistance Publique Hopitaux de Paris, Le 
      Kremlin-Bicetre, France.
FAU - Pittrow, David
AU  - Pittrow D
AD  - Institute for Clinical Pharmacology, Medical Faculty, Technical University, 
      Dresden, Germany.
FAU - Delcroix, Marion
AU  - Delcroix M
AD  - Clinical Department of Respiratory Diseases, University Hospitals and Laboratory 
      of Respiratory Diseases and Thoracic Surgery and Department of Chronic Diseases 
      and Metabolism, KU Leuven, University of Leuven, Leuven, Belgium.
FAU - Pepke-Zaba, Joanna
AU  - Pepke-Zaba J
AD  - Pulmonary Vascular Disease Unit, Royal Papworth Hospital, Cambridge, UK.
FAU - Langleben, David
AU  - Langleben D
AD  - Jewish General Hospital, McGill University, Montreal, Quebec, Canada.
FAU - Mielniczuk, Lisa M
AU  - Mielniczuk LM
AD  - Division of Cardiology, Department of Medicine, University of Ottawa Heart 
      Institute, Ottawa, Ontario, Canada.
FAU - Escribano Subias, Pilar
AU  - Escribano Subias P
AD  - Cardiology Department and Spanish Cardiovascular Research Network, Hospital 
      Universitario 12 de Octubre, Madrid, Spain.
FAU - Snijder, Repke J
AU  - Snijder RJ
AD  - Department of Pulmonology, St Antonius Ziekenhuis, Nieuwegein, The Netherlands.
FAU - Barbera, Joan A
AU  - Barbera JA
AD  - Department of Pulmonary Medicine, Hospital Clinic-IDIBAPS, University of 
      Barcelona, and Biomedical Research Networking Center on Respiratory Diseases, 
      Madrid, Spain.
FAU - Klotsche, Jens
AU  - Klotsche J
AD  - German Rheumatism Research Centre Berlin, Leibniz Institute, Berlin, Germany.
FAU - Meier, Christian
AU  - Meier C
AD  - Bayer AG, Global Medical Affairs, Berlin, Germany.
FAU - Hoeper, Marius M
AU  - Hoeper MM
AD  - Clinic for Respiratory Medicine, Hannover Medical School, German Center for Lung 
      Research, Hannover, Germany.
LA  - eng
PT  - Journal Article
PT  - Multicenter Study
PT  - Research Support, Non-U.S. Gov't
DEP - 20220211
PL  - United States
TA  - J Heart Lung Transplant
JT  - The Journal of heart and lung transplantation : the official publication of the 
      International Society for Heart Transplantation
JID - 9102703
RN  - 0 (Anticoagulants)
RN  - 12001-79-5 (Vitamin K)
SB  - IM
MH  - Administration, Oral
MH  - Anticoagulants/adverse effects
MH  - *Atrial Fibrillation
MH  - Cohort Studies
MH  - Hemorrhage/chemically induced
MH  - Humans
MH  - *Hypertension, Pulmonary/chemically induced/complications/drug therapy
MH  - Prospective Studies
MH  - Vitamin K
OTO - NOTNLM
OT  - chronic thromboembolic pulmonary hypertension
OT  - drug safety
OT  - non-vitamin K antagonist oral anticoagulants
OT  - riociguat
OT  - vitamin K antagonists
EDAT- 2022/03/21 06:00
MHDA- 2022/05/26 06:00
CRDT- 2022/03/20 20:26
PHST- 2021/09/10 00:00 [received]
PHST- 2022/01/21 00:00 [revised]
PHST- 2022/02/04 00:00 [accepted]
PHST- 2022/03/21 06:00 [pubmed]
PHST- 2022/05/26 06:00 [medline]
PHST- 2022/03/20 20:26 [entrez]
AID - S1053-2498(22)01804-6 [pii]
AID - 10.1016/j.healun.2022.02.002 [doi]
PST - ppublish
SO  - J Heart Lung Transplant. 2022 Jun;41(6):716-721. doi: 
      10.1016/j.healun.2022.02.002. Epub 2022 Feb 11.